Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Accumulated Expenses (2016 - 2025)

Cytokinetics (CYTK) has disclosed Accumulated Expenses for 16 consecutive years, with $33.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Accumulated Expenses changed N/A to $33.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was $33.2 million, a N/A change, with the full-year FY2023 number at $42.6 million, down 3.3% from a year prior.
  • Accumulated Expenses was $33.2 million for Q3 2025 at Cytokinetics, down from $52.3 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $52.3 million in Q2 2025 to a low of $7.0 million in Q1 2021.
  • A 5-year average of $29.2 million and a median of $33.0 million in 2023 define the central range for Accumulated Expenses.
  • Peak YoY movement for Accumulated Expenses: skyrocketed 195.35% in 2022, then plummeted 54.63% in 2024.
  • Cytokinetics' Accumulated Expenses stood at $14.9 million in 2021, then soared by 195.35% to $44.1 million in 2022, then fell by 3.3% to $42.6 million in 2023, then crashed by 53.09% to $20.0 million in 2024, then surged by 65.96% to $33.2 million in 2025.
  • Per Business Quant, the three most recent readings for CYTK's Accumulated Expenses are $33.2 million (Q3 2025), $52.3 million (Q2 2025), and $20.0 million (Q2 2024).